Economic Burden of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring KRASG12C Mutation in Spain
Author(s)
Fernández-Barceló C1, Abbas I1, Botella X2, Aguiló Domingo M2, Cots F3, Siles Cuesta C3, Arriola E3, Gas López ME4, López Gómez C4, Juan-Vidal O5, Planellas L6, Lloansí A6, Sánchez J1, Reguart N1, Sampietro-Colom L1
1Hospital Clínic de Barcelona, Barcelona, Spain, 2Consorci Sanitari de Terrassa, Terrassa, Spain, 3Hospital del Mar-CIBERONC, Barcelona, Spain, 4The Health Research Institute Hospital La Fe, Valencia, Spain, 5Hospital La Fe de Valencia, Valencia, Spain, 6Amgen S.A., Barcelona, Spain
Presentation Documents
OBJECTIVES: To characterize the costs of healthcare resources used in locally advanced/metastatic NSCLC KRASG12C-mutated patients in Spain, as these data have not yet been reported.
METHODS: Observational, retrospective, multicenter study in patients with locally advanced (not candidate for radical treatment) or metastatic NSCLC and KRASG12C mutated. Clinical and economic data were collected from medical records and administrative databases from 1st Jan 2016 to 9th Mar 2022 (diagnosis: Jan2016-Oct2021). Patients participating in clinical trials with KRAS inhibitors were excluded. Mean cost and 95% confidence interval (CI) were calculated for total and disease-related healthcare costs. A sub-analysis was conducted by treatment line and received therapy (alone or in combination: chemotherapy, immunotherapy, or other systemic therapies) for disease-related costs.
RESULTS: 125 and 104 patients had total and disease-related healthcare resource data available, respectively. The estimated total and disease-related cost over the study period were €5.725.934 (mean cost per patient: €46.177 [95%CI: €37.680-€54.674]) and €4.238.525 (mean cost per patient: €41.151 [95%CI: €32.343-49.958]), respectively. Mean (95%CI) disease-related cost per patient in 1st line (1L), 2nd line (2L), and 3rd line and later (3L+) was €39.860 (€30.337-€49.383), €26.698 (€16.938-€36.458), and €19.874 (€1.965-€37.783), respectively. Drug use was the main cost driver: 61% in 1L, and 51% in 2L and 3L+. Main cost driver among other healthcare resources used were hospitalizations in 1L (40%) and 2L (50%), and visits (day hospital and to healthcare professionals) in 3L+ (51%).
CONCLUSIONS: This study provides evidence on advanced KRASG12C-mutated NSCLC economic burden in Spain. Mean cost per patient decreased across treatment lines, and the cost associated to hospitalizations appears to be more relevant in 1L and 2L. The management of these patients remains a relevant burden for patients and health systems, highlighting the need for new treatment options.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
RWD89
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Drugs, Oncology